Brendan Teehan - 29 Apr 2022 Form 4 Insider Report for ACADIA PHARMACEUTICALS INC (ACAD)

Role
EVP, COO, Head of Commercial
Signature
/s/ Austin D. Kim, Attorney-in-Fact
Issuer symbol
ACAD
Transactions as of
29 Apr 2022
Transactions value $
-$10,036
Form type
4
Filing time
03 May 2022, 20:47:20 UTC
Previous filing
07 Apr 2022
Next filing
10 Jan 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ACAD Common Stock Options Exercise +1.57K +64.7% 3.99K 29 Apr 2022 Direct F1
transaction ACAD Common Stock Sale -$10K -552 -13.84% $18.18 3.44K 02 May 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ACAD Restricted Stock Units Options Exercise $0 -1.57K -50% $0.00 1.57K 29 Apr 2022 Common Stock 1.57K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit represents a contingent right to receive one share of Acadia common stock.
F2 The sales reported in this Form 4 were made to cover the tax obligation that occurred upon the vesting of restricted stock units.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $18.18 to $18.4025, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
F4 50% of the shares subject to the restricted stock units vest on each of April 29, 2022 and April 29, 2023.